CMS announces broad state participation in the GENEROUS Medicaid drug payment model and a September 30 signing date
Sep 27, 2026 edition · GC-2026-0106 · Published 2026-09-27 · Version 2 · Announced
CMS reports applications from every state, DC and Puerto Rico, but fewer signed GENEROUS agreements. The September 30 signing date remains ahead; applications alone do not establish each state’s participation terms.
What happened
CMS announced September 18 that all 50 states, the District of Columbia and Puerto Rico had applied for the GENEROUS Medicaid drug-payment model. Forty states and Puerto Rico had signed participation agreements at the time of that release, with the remainder given until September 30. CMS describes the model as having launched in January 2026 for five years and estimates $64.3 billion in taxpayer savings over ten years. The estimate is a forecast, and the broad application count is distinct from the smaller signed-agreement count reported on September 18.
Participating manufacturers make covered outpatient drugs available to participating state programs at most-favored-nation prices through supplemental rebates invoiced under state agreements. CMS monitors pricing accuracy and shares in the rebates through a reduction in the federal share of Medicaid payments. Those mechanics create state, manufacturer and federal accounting dependencies rather than an automatic new provider payment rate. At this September coverage cutoff, the September 30 signing date remains ahead. The release does not establish California’s final agreement status or that every applicant will sign. State-specific terms and operational instructions remain necessary to assess downstream effects.
Scope and timing
- Authority status
- Announced
- Applicability
- Directly applicable
- Audience
- Health systems, Provider networks
- Jurisdiction
- Federal, California
- Affected functions
- Managed Care, Clinical Operations, Finance, Compliance, IT
- Responsible owner
- Managed Care
- Recorded date
- 2026-09-30
- Date type
- implementation
Why it matters
Rebate invoicing, pricing verification and federal-share reconciliation can change financial operations without automatically changing every formulary or provider claim.
Recommended action
Confirm California’s actual agreement status and responsible state contact before the September 30 milestone. Map supplemental-rebate invoicing, pricing verification and federal-share reconciliation before changing forecasts or downstream claims rules.
Implementation playbook
- Internal target: Confirm California participation status and the state implementation contact. Managed Care · Due 2026-09-23
- Internal target: Map supplemental-rebate invoicing, manufacturer data, and federal-share reconciliation dependencies. Finance · Due 2026-09-30
- Internal target: Monitor DHCS instructions for formulary, claims, or reporting changes. Clinical Operations · Due 2026-10-07
Sources
- CMS Announces Participants in Landmark Medicaid Drug Payment Model to Bring Down Drug Costs for Most Vulnerable AmericansOfficial · Centers for Medicare and Medicaid Services · 2026-09-18 · Source review 2026-09-20
Complete edition and supplemental material
This finding in the complete approved report →Regulatory horizons, CIA trends and implementation trackers remain in the full report.
Read the entire Medicare & Medicaid report →